P Vestergaard1, N R Jorgensen, P Schwarz, L Mosekilde. 1. The Osteoporosis Clinic, Department of Endocrinology and Metabolism C, Aarhus University Hospital Aarhus Amtssygehus, Tage Hansens Gade 2, 8000 Aarhus C, Denmark. p-vest@post4.tele.dk
Abstract
UNLABELLED: Fluoride has fallen into discredit due to the absence of an anti-fracture effect. However, in this meta-analysis, a fracture reducing potential was seen at low fluoride doses [< or =20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride)]: OR = 0.3, 95% CI: 0.1-0.9 for vertebral and OR = 0.5, 95% CI: 0.3-0.8 for non-vertebral fractures. INTRODUCTION: Fluoride is incorporated into bone mineral and has an anabolic effect. However, the biomechanical competence of the newly formed bone may be reduced. METHODS: A systematic search of PubMed, Embase, and ISI web of science yielded 2,028 references. RESULTS: Twenty-five eligible studies were identified. Spine BMD increased 7.9%, 95% CI: 5.4-10.5%, and hip BMD 2.1%, 95% CI: 0.9-3.4%. A meta-regression showed increasing spine BMD with increasing treatment duration (5.04 +/- 2.16%/year of treatment). Overall there was no significant effect on the risk of vertebral (OR = 0.8, 95% CI: 0.5-1.5) or non-vertebral fracture (OR = 0.8, 95% CI: 0.5-1.4). With a daily dose of < or =20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride), there was a statistically significant reduction in vertebral (OR = 0.3, 95% CI: 0.1-0.9) and non-vertebral (OR = 0.5, 95% CI: 0.3-0.8) fracture risk. With a daily dose >20 mg fluoride equivalents, there was no significant reduction in vertebral (OR = 1.3, 95% CI: 0.8-2.0) and non-vertebral (OR = 1.5, 95% CI: 0.8-2.8) fracture risk. CONCLUSIONS: Fluoride treatment increases spine and hip BMD, depending on treatment duration. Overall there was no effect on hip or spine fracture risk. However, in subgroup analyses a low fluoride dose (< or =20 mg/day of fluoride equivalents) was associated with a significant reduction in fracture risk.
UNLABELLED: Fluoride has fallen into discredit due to the absence of an anti-fracture effect. However, in this meta-analysis, a fracture reducing potential was seen at low fluoride doses [< or =20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride)]: OR = 0.3, 95% CI: 0.1-0.9 for vertebral and OR = 0.5, 95% CI: 0.3-0.8 for non-vertebral fractures. INTRODUCTION:Fluoride is incorporated into bone mineral and has an anabolic effect. However, the biomechanical competence of the newly formed bone may be reduced. METHODS: A systematic search of PubMed, Embase, and ISI web of science yielded 2,028 references. RESULTS: Twenty-five eligible studies were identified. Spine BMD increased 7.9%, 95% CI: 5.4-10.5%, and hip BMD 2.1%, 95% CI: 0.9-3.4%. A meta-regression showed increasing spine BMD with increasing treatment duration (5.04 +/- 2.16%/year of treatment). Overall there was no significant effect on the risk of vertebral (OR = 0.8, 95% CI: 0.5-1.5) or non-vertebral fracture (OR = 0.8, 95% CI: 0.5-1.4). With a daily dose of < or =20 mg fluoride equivalents (152 mg monofluorophosphate/44 mg sodium fluoride), there was a statistically significant reduction in vertebral (OR = 0.3, 95% CI: 0.1-0.9) and non-vertebral (OR = 0.5, 95% CI: 0.3-0.8) fracture risk. With a daily dose >20 mg fluoride equivalents, there was no significant reduction in vertebral (OR = 1.3, 95% CI: 0.8-2.0) and non-vertebral (OR = 1.5, 95% CI: 0.8-2.8) fracture risk. CONCLUSIONS:Fluoride treatment increases spine and hip BMD, depending on treatment duration. Overall there was no effect on hip or spine fracture risk. However, in subgroup analyses a low fluoride dose (< or =20 mg/day of fluoride equivalents) was associated with a significant reduction in fracture risk.
Authors: C von Tirpitz; J Klaus; M Steinkamp; L C Hofbauer; W Kratzer; R Mason; B O Boehm; G Adler; M Reinshagen Journal: Aliment Pharmacol Ther Date: 2003-03-15 Impact factor: 8.171
Authors: B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton Journal: N Engl J Med Date: 1990-03-22 Impact factor: 91.245
Authors: P J Meunier; J L Sebert; J Y Reginster; D Briancon; T Appelboom; P Netter; G Loeb; A Rouillon; S Barry; J C Evreux; B Avouac; X Marchandise Journal: Osteoporos Int Date: 1998 Impact factor: 4.507
Authors: J Y Reginster; L Meurmans; B Zegels; L C Rovati; H W Minne; G Giacovelli; A N Taquet; I Setnikar; J Collette; C Gosset Journal: Ann Intern Med Date: 1998-07-01 Impact factor: 25.391
Authors: G Iolascon; R Gimigliano; M Bianco; A De Sire; A Moretti; A Giusti; N Malavolta; S Migliaccio; A Migliore; N Napoli; P Piscitelli; G Resmini; U Tarantino; F Gimigliano Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: S M Levy; J J Warren; K Phipps; E Letuchy; B Broffitt; J Eichenberger-Gilmore; T L Burns; G Kavand; K F Janz; J C Torner; C A Pauley Journal: J Dent Res Date: 2014-01-27 Impact factor: 6.116